Literature DB >> 11177694

Should patients with chronic hepatitis C who have normal ALT levels be treated?

M W Russo1, R S Brown.   

Abstract

Up to 25% of patients with chronic hepatitis C have persistently normal serum alanine aminotransferase (ALT) levels. Reports from some studies indicate that patients with normal ALT levels are more likely to be female and nondrinkers. Patients with persistently normal aminotransferase levels often have mild disease on liver biopsy with little or no fibrosis, but a small number of patients may have substantial fibrosis or cirrhosis. Treatment with interferon monotherapy has been disappointing. Combination therapy with interferon and ribavirin is controversial, but early clinical results have shown good response rates. Currently, therapy for chronic HCV patients with normal ALT levels should be based upon results from liver biopsy and preferably be done in the context of a clinical trial.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11177694     DOI: 10.1007/s11894-001-0040-5

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  19 in total

1.  Virological response to interferon treatment in hepatitis C virus carriers with normal aminotransferase levels and chronic hepatitis.

Authors:  A Rossini; A Ravaggi; L Biasi; E Agostinelli; L Bercich; G B Gazzola; F Callea; E Radaeli; E Cariani
Journal:  Hepatology       Date:  1997-10       Impact factor: 17.425

2.  Sequence variation of the hypervariable region in HCV carriers with normal ALT levels: a comparison with symptomatic carriers.

Authors:  S Murashima; M Sata; H Suzuki; S Noguchi; K Tanikawa
Journal:  Microbiol Immunol       Date:  1996       Impact factor: 1.955

Review 3.  Therapy of hepatitis C: patients with normal aminotransferase levels.

Authors:  P Marcellin; S Lévy; S Erlinger
Journal:  Hepatology       Date:  1997-09       Impact factor: 17.425

4.  Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels.

Authors:  M Persico; E Persico; R Suozzo; S Conte; M De Seta; L Coppola; B Palmentieri; F C Sasso; R Torella
Journal:  Gastroenterology       Date:  2000-04       Impact factor: 22.682

5.  Clinical features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the Southwestern United States.

Authors:  M M Jamal; A Soni; P G Quinn; D E Wheeler; S Arora; D E Johnston
Journal:  Hepatology       Date:  1999-11       Impact factor: 17.425

6.  Interferon-alpha 2b therapy in low-activity hepatitis C: a pilot study.

Authors:  I Nordøy; H B Krarup; H Bell; P B Christensen; K Elgjo; B von der Lippe; O S De Muckadell; A Maeland; H Ring-Larsen; H H Samdal; P Simmonds; K Skaug; U Tage-Jensen; E Schrumpf
Journal:  Scand J Gastroenterol       Date:  1997-12       Impact factor: 2.423

7.  Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity.

Authors:  P Mathurin; J Moussalli; J F Cadranel; V Thibault; F Charlotte; P Dumouchel; A Cazier; J M Huraux; B Devergie; M Vidaud; P Opolon; T Poynard
Journal:  Hepatology       Date:  1998-03       Impact factor: 17.425

8.  Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: a pilot randomized controlled study.

Authors:  A Sangiovanni; R Morales; G Spinzi; M Rumi; A Casiraghi; R Ceriani; E Colombo; M Fossati; A Prada; E Tavani; G Minoli
Journal:  Hepatology       Date:  1998-03       Impact factor: 17.425

9.  Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities.

Authors:  E Silini; F Bono; A Cividini; A Cerino; S Bruno; S Rossi; G Belloni; B Brugnetti; E Civardi; L Salvaneschi
Journal:  Hepatology       Date:  1995-02       Impact factor: 17.425

10.  Hepatitis C viral quasispecies in hepatitis C virus carriers with normal liver enzymes and patients with type C chronic liver disease.

Authors:  M Naito; N Hayashi; T Moribe; H Hagiwara; E Mita; Y Kanazawa; A Kasahara; H Fusamoto; T Kamada
Journal:  Hepatology       Date:  1995-08       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.